Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Bolaños-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, Fuchs EJ, Gladstone DE, Gocke CB, Huff CA, Luznik L, Swinnen LJ, Symons HJ, Terezakis SA, Wagner-Johnston N, Jones RJ, Brodsky RA.

Lancet Haematol. 2019 Mar 13. pii: S2352-3026(19)30031-6. doi: 10.1016/S2352-3026(19)30031-6. [Epub ahead of print]


Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

McCurdy SR, Muth ST, Tsai HL, Symons HJ, Huff CA, Matsui WH, Borrello I, Gladstone DE, Swinnen LJ, Cooke KR, Brodsky RA, Bolaños-Meade J, Ambinder RF, Varadhan R, Luznik L, Jones RJ, Bettinot MP, Fuchs EJ.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2056-2064. doi: 10.1016/j.bbmt.2018.06.004. Epub 2018 Jun 15.


Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.


Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, Luber B, Rosner G, Siegel N, Holuba MJ, Robey N, Hayashi M, Jones RJ, Fuchs E, Holdhoff M, Loeb DM, Symons HJ.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2127-2136. doi: 10.1016/j.bbmt.2017.08.012. Epub 2017 Aug 12.


Patients' and Parents' Needs, Attitudes, and Perceptions About Early Palliative Care Integration in Pediatric Oncology.

Levine DR, Mandrell BN, Sykes A, Pritchard M, Gibson D, Symons HJ, Wendler D, Baker JN.

JAMA Oncol. 2017 Sep 1;3(9):1214-1220. doi: 10.1001/jamaoncol.2017.0368.


Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.

Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH, Cooke KR, O'Donnell PV, Symons HJ, Paczesny S, Luznik L.

Haematologica. 2017 May;102(5):932-940. doi: 10.3324/haematol.2016.152322. Epub 2017 Jan 25.


Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Bolaños-Meade J, Swinnen L, Kanakry J, Luznik L, Jones RJ, Fuchs E, Ambinder R, Kasamon Y, Symons HJ.

Biol Blood Marrow Transplant. 2017 Apr;23(4):612-617. doi: 10.1016/j.bbmt.2016.12.640. Epub 2017 Jan 3.


Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, Zambidis E, Llosa NJ, Huo JS, Robey N, Holuba MJ, Kasamon YL, McCurdy SR, Ambinder R, Bolaños-Meade J, Luznik L, Fuchs EJ, Jones RJ, Cooke KR, Symons HJ.

Biol Blood Marrow Transplant. 2017 Feb;23(2):325-332. doi: 10.1016/j.bbmt.2016.11.016. Epub 2016 Nov 22.


Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.


High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.

Gamper CJ, Takemoto CM, Chen AR, Symons HJ, Loeb DM, Casella JF, Dezern AE, King KE, McGonigle AM, Jones RJ, Brodsky RA.

J Pediatr Hematol Oncol. 2016 Nov;38(8):627-635.


Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report.

Shad AT, Huo JS, Darcy C, Abu-Ghosh A, Esposito G, Holuba MJ, Robey N, Cooke KR, Symons HJ, Chen AR, Llosa NJ.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26257. Epub 2016 Sep 21.


Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report.

Huo JS, Symons HJ, Robey N, Borowitz MJ, Schafer ES, Chen AR.

Pediatr Blood Cancer. 2016 Jul;63(7):1279-82. doi: 10.1002/pbc.25971. Epub 2016 Mar 14.


Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.

Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, Dezern AE, Steppan D, Robey N, Holuba MJ, Cooke KR, Symons HJ.

Biol Blood Marrow Transplant. 2016 May;22(5):895-901. doi: 10.1016/j.bbmt.2016.02.001. Epub 2016 Feb 6.


Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.

Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ.

Biol Blood Marrow Transplant. 2016 Jan;22(1):112-8. doi: 10.1016/j.bbmt.2015.08.034. Epub 2015 Sep 4.


Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.


New frontiers in pediatric Allo-SCT.

Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, Hancock L, Morris E, Cairo MS.

Bone Marrow Transplant. 2014 Sep;49(9):1139-45. doi: 10.1038/bmt.2014.89. Epub 2014 May 12. Review.


Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.

Shah NN, Borowitz MJ, Steinberg SM, Robey NC, Gamper CJ, Symons HJ, Loeb DM, Wayne AS, Chen AR.

Biol Blood Marrow Transplant. 2014 Jul;20(7):1033-9. doi: 10.1016/j.bbmt.2014.03.028. Epub 2014 Mar 30.


Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.

Shah NN, Borowitz MJ, Robey NC, Gamper CJ, Symons HJ, Loeb DM, Wayne AS, Chen AR.

Biol Blood Marrow Transplant. 2014 Jul;20(7):1000-7. doi: 10.1016/j.bbmt.2014.03.021. Epub 2014 Mar 27.


Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.

DeZern AE, Symons HJ, Resar LS, Borowitz MJ, Armanios MY, Brodsky RA.

Eur J Haematol. 2014 Jun;92(6):467-70. doi: 10.1111/ejh.12299. Epub 2014 Mar 18.


Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Kanakry JA, Kasamon YL, Bolaños-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen LJ, Symons HJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1514-7. doi: 10.1016/j.bbmt.2013.07.013. Epub 2013 Jul 18.


Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.

Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ.

Pediatr Rep. 2011 Jun 22;3 Suppl 2:e15. doi: 10.4081/pr.2011.s2.e15.


Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ.

Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42. doi: 10.1016/j.bbmt.2009.11.022. Epub 2009 Dec 2.


Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher MA, Petersen FB, Storb R, Fuchs EJ, Maloney DG.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87. doi: 10.1016/j.bbmt.2008.08.014.


Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Symons HJ, Fuchs EJ.

Bone Marrow Transplant. 2008 Sep;42(6):365-77. doi: 10.1038/bmt.2008.215. Epub 2008 Aug 4. Review.


HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ.

Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.


The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.

Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE, Luznik L, Levitsky HI, Fuchs EJ.

Biol Blood Marrow Transplant. 2008 May;14(5):499-509. doi: 10.1016/j.bbmt.2008.02.013.


[Works in the Wellcome Library].

van Pelt RJ, Getz FM, Symons HJ.

Kos. 1984 Sep;1(7):104-8. Italian. No abstract available.


A Large Urethral Calculus.

Symons HJH.

Ind Med Gaz. 1934 Jul;69(7):394. No abstract available.

Supplemental Content

Loading ...
Support Center